Shares of animal health leader Zoetis Inc. (ZTS) traded lower this week following a subdued financial outlook for 2026. The stock's underperformance was highlighted in Diamond Hill Capital's latest investor letter, which contrasted the company's challenges against a broader market rally fueled by AI optimism.
After a steep 18% drop in January, Palantir Technologies shares rebounded sharply on the back of a strong quarterly report, highlighting the intense scrutiny facing high-flying AI stocks.
A group of former Dell Technologies employees has filed a federal lawsuit accusing the company of breaching its fiduciary duties by retaining underperforming in-house funds in its $14.6 billion retirement plan, allegedly costing participants over $318 million.
Pfizer reported a Q4 loss driven by steep declines in its COVID-19 vaccine and antiviral sales, while highlighting promising early data for a newly acquired GLP-1 weight-loss therapy as it seeks to diversify its revenue stream.
While major cryptocurrencies plummet to multi-year lows, the total value locked in decentralized finance protocols has shown remarkable stability, suggesting a maturing sector and continued investor commitment to yield generation.
Russia's leading financial marketplace is set to introduce ruble-settled futures contracts for three major altcoins, broadening access to crypto derivatives for qualified investors amid a shifting regulatory landscape.
Despite a strong quarterly market rally led by tech, Diamond Hill Capital's Large Cap Fund underperformed, citing caution on AI hype. Food distribution giant Sysco was a notable laggard in the fund's portfolio, with analysts pointing to broader concerns over consumer spending and the restaurant industry's outlook.
As Saudi Arabia launches a National Savings Strategy, fintech startup Hakbah is bringing the traditional 'jameya' savings model online, tapping into a young user base and awaiting pivotal new regulations to scale its impact.
CNBC's Jim Cramer attributes Monday's pre-market pressure on S&P 500 futures to a cascading sell-off in gold and silver, arguing forced liquidations by over-leveraged commodity traders are creating a buying opportunity disconnected from corporate fundamentals.
A staggering 83% ownership of Eaton Corporation by institutional investors creates a landscape of concentrated power, where major fund moves could dictate the stock's volatility and future trajectory.
The Austin-based fitness franchisor, backed by actor Mark Wahlberg, has reached a settlement in a class-action lawsuit. Shareholders alleged the company inflated its growth prospects prior to its 2021 public listing, which was followed by a steep decline in value and its removal from the NYSE.
Diamond Hill Capital's latest investor letter highlights General Motors' resilient performance in Q4 2025, even as the fund expresses caution toward AI-driven market euphoria and lags behind the broader value index.
Citi Research has initiated coverage on Sanofi with a Neutral rating and an €85 price target, citing pipeline setbacks and a lack of near-term catalysts. The analysis comes as the French pharma giant reports positive Phase 3 results for its eczema drug amlitelimab.
Elon Musk consolidates his space and AI ventures as SpaceX acquires xAI, with a combined valuation nearing $1.25 trillion. The move precedes a highly anticipated SpaceX IPO that could become the largest in history and reignite the global market for new listings.
Mizuho Securities lowered its price target for Qualcomm, citing a weaker outlook for global smartphone shipments and increased competition. The firm projects a potential decline in handset production and pressures from rising memory costs.
The maker of SuperPretzel and ICEE brands reported quarterly sales of $343.8 million, falling short of Wall Street forecasts and marking a year-over-year decline. Adjusted earnings also missed analyst expectations.
PJT Partners reported fourth-quarter revenue that fell short of analyst expectations, though earnings per share topped estimates and year-over-year sales growth remained robust at 12.1%, highlighting the advisory-focused bank's resilient performance in a challenging market.
Merck & Co. reported solid fourth-quarter revenue growth driven by its blockbuster cancer drug Keytruda, but the pharmaceutical giant forecasts a slowdown in earnings growth as it absorbs billions in costs from recent acquisitions aimed at diversifying its pipeline ahead of Keytruda's patent expiration.
Ingredion (NYSE: INGR) reported fourth-quarter revenue of $1.76 billion, missing analyst expectations and marking a 2.4% year-over-year decline. Adjusted earnings per share also came in below consensus.
As artificial intelligence transforms every sector, CEOs are under unprecedented pressure to demonstrate fluency and generate returns. This new mandate is shortening tenures, favoring a younger, more adaptable generation of leaders, and redefining the very skills required to steer a modern enterprise.
